September 27, 2019
Ribometrix announces $7.8 M in new funding to advance RNA-Targeting drug discovery platform
Company appoints Flexion Therapeutics CEO Mike Clayman as board chairman DURHAM, N.C.–(BUSINESS WIRE)–Ribometrix, a biotechnology company developing small molecule therapeutics…